Naz Rahman
Stock Analyst at Maxim Group
(0.28)
# 4,466
Out of 5,245 analysts
38
Total ratings
18.18%
Success rate
-40.37%
Average return
Main Sectors:
Stocks Rated by Naz Rahman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Upgrades: Buy | $575 | $434.52 | +32.33% | 2 | Mar 18, 2026 | |
| NXGL NEXGEL | Maintains: Buy | $6 → $2 | $0.54 | +270.37% | 2 | Mar 12, 2026 | |
| SCNX Scienture Holdings | Initiates: Buy | $1.5 | $0.402 | +273.13% | 1 | Feb 24, 2026 | |
| KZIA Kazia Therapeutics | Maintains: Buy | $15 → $20 | $13.66 | +46.41% | 1 | Oct 2, 2025 | |
| AYTU Aytu BioPharma | Maintains: Buy | $9 → $7 | $2.18 | +221.84% | 2 | Sep 25, 2025 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Hold | n/a | $0.5801 | - | 1 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiates: Buy | $17 | $10.35 | +64.25% | 1 | Apr 2, 2025 | |
| SLXN Silexion Therapeutics | Maintains: Buy | $135 → $75 | $0.50 | +14,900.00% | 2 | Mar 20, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $120 → $70 | $30.89 | +126.61% | 5 | Feb 7, 2025 | |
| NRSN NeuroSense Therapeutics | Downgrades: Hold | n/a | $0.82 | - | 2 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $4.47 | - | 4 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $8 | $1.95 | +310.26% | 7 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.49 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $23.44 | +91.98% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $140 | $4.77 | +2,835.01% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.65 | - | 3 | Nov 17, 2023 |
Vertex Pharmaceuticals
Mar 18, 2026
Upgrades: Buy
Price Target: $575
Current: $434.52
Upside: +32.33%
NEXGEL
Mar 12, 2026
Maintains: Buy
Price Target: $6 → $2
Current: $0.54
Upside: +270.37%
Scienture Holdings
Feb 24, 2026
Initiates: Buy
Price Target: $1.5
Current: $0.402
Upside: +273.13%
Kazia Therapeutics
Oct 2, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $13.66
Upside: +46.41%
Aytu BioPharma
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $7
Current: $2.18
Upside: +221.84%
Galmed Pharmaceuticals
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.5801
Upside: -
Nuvectis Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $17
Current: $10.35
Upside: +64.25%
Silexion Therapeutics
Mar 20, 2025
Maintains: Buy
Price Target: $135 → $75
Current: $0.50
Upside: +14,900.00%
Viking Therapeutics
Feb 7, 2025
Maintains: Buy
Price Target: $120 → $70
Current: $30.89
Upside: +126.61%
NeuroSense Therapeutics
Dec 16, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.82
Upside: -
Nov 20, 2024
Upgrades: Buy
Price Target: n/a
Current: $4.47
Upside: -
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $8
Current: $1.95
Upside: +310.26%
Oct 24, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.49
Upside: -
Jul 26, 2024
Initiates: Buy
Price Target: $45
Current: $23.44
Upside: +91.98%
Mar 15, 2024
Maintains: Buy
Price Target: $525 → $140
Current: $4.77
Upside: +2,835.01%
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.65
Upside: -